Repository logo
 

The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT3A and 5-HT3AB receptors.


Change log

Authors

Thompson, Andrew J 
Verheij, Mark HP 
Verbeek, Joost 
Windhorst, Albert D 
de Esch, Iwan JP 

Abstract

VUF10166 (2-chloro-3-(4-methyl piperazin-1-yl)quinoxaline) is a ligand that binds with high affinity to 5-HT3 receptors. Here we synthesise [(3)H]VUF10166 and characterise its binding properties at 5-HT3A and 5-HT3AB receptors. At 5-HT3A receptors [(3)H]VUF10166 displayed saturable binding with a Kd of 0.18 nM. Kinetic measurements gave monophasic association (6.25 × 10(7) M(-1) min(-1)) and dissociation (0.01 min(-1)) rates that yielded a similar Kd value (0.16 nM). At 5-HT3AB receptors two association (6.15 × 10(-7), 7.23 M(-1) min(-1)) and dissociation (0.024, 0.162 min(-1)) rates were seen, yielding Kd values (0.38 nM and 22 nM) that were consistent with values obtained in saturation (Kd = 0.74 nM) and competition (Ki = 37 nM) binding experiments respectively. At both receptor types, specific binding was inhibited by classical 5-HT3 receptor-selective orthosteric ligands (5-HT, allosetron, d-tubocurarine, granisetron, mCPBG, MDL72222, quipazine), but not by non-competitive antagonists (bilobalide, ginkgolide B, picrotoxin) or competitive ligands of other Cys-loop receptors (ACh, bicuculline, glycine, gabazine). To explore VUF10166 ligand-receptor interactions we used in silico modelling and docking, and tested the predictions using site directed mutagenesis. The data suggest that VUF10166 adopts a similar orientation to 5-HT3 receptor agonists bound in AChBP (varenicline) and 5HTBP (5-HT) crystal structures.

Description

Keywords

5-HT(3), Agonist, Antagonist, Cys-loop, Ion channel, Radioligand, Amino Acid Sequence, Binding, Competitive, HEK293 Cells, Humans, Molecular Docking Simulation, Molecular Sequence Data, Mutagenesis, Site-Directed, Piperidines, Quinoxalines, Radioligand Assay, Radiopharmaceuticals, Receptors, Serotonin, 5-HT3, Sequence Alignment, Tritium

Journal Title

Neuropharmacology

Conference Name

Journal ISSN

0028-3908
1873-7064

Volume Title

86

Publisher

Elsevier BV
Sponsorship
Wellcome Trust (081925/Z/07/A)